Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
27/07/2026 22:24
BRIEF-Sellas Life Sciences Group - Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing July 27 (Reuters) - Sellas Life Sciences Group Inc SLS.O:
SELLAS LIFE SCIENCES GROUP - ARBITRATOR DISMISSES COMPANY'S CLAIMS IN ARBITRATION AGAINST 3D MEDICINES ON JULY 24, 2026 - SEC FILING
SELLAS LIFE SCIENCES GROUP - COMPANY TO PAY ABOUT $1 MILLION OF 3D MEDICINES' LEGAL FEES - SEC FILING
SELLAS LIFE SCIENCES GROUP INC: 3D MEDICINES WILL CONTINUE DEVELOPMENT & COMMERCIALIZATION OF GALINPEPIMUT-S IN GREATER CHINA TERRITORY
Source text: [ID:n0001104659-26-087110]
Further company coverage: SLS.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on 3D Medicines
See all newsArbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
Brief: 3D Medicines Updates On Arbitration Proceedings Against Sellas Life Sciences
Brief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Brief: 3D Medicines Inc Says Zhang Jing Resigns As CFO
Brief: 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted